Unknown

Dataset Information

0

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial.


ABSTRACT: A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.

SUBMITTER: Wiriyatanakorn S 

PROVIDER: S-EPMC6641787 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial.

Wiriyatanakorn Sirichai S   Sungkanuparph Somnuek S  

Open forum infectious diseases 20190626 7


A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects. ...[more]

Similar Datasets

| S-EPMC6221083 | biostudies-literature
| S-EPMC7288166 | biostudies-literature
| S-EPMC6410964 | biostudies-literature
| S-EPMC4576083 | biostudies-literature
| S-EPMC6844404 | biostudies-literature
| S-EPMC5681370 | biostudies-literature
| S-EPMC3985528 | biostudies-literature
| S-EPMC6097579 | biostudies-literature
| S-EPMC5669010 | biostudies-literature
| S-EPMC4319732 | biostudies-literature